Eli Lilly & Co.

LLY-N

NYSE:LLY

141.21
0.35 (0.25%)
Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
More at Wikipedia

Analysis and Opinions about LLY-N

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
July 13, 2005
Prefers others such as Abbott Labs (ABT-N).
Show full opinionHide full opinion
Prefers others such as Abbott Labs (ABT-N).
WEAK BUY
WEAK BUY
May 3, 2005
Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics.
Show full opinionHide full opinion
Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics.
BUY
BUY
March 15, 2005
A little bit of risk in a 3/6 month view as to whether they can retain their patent on Sprizecta (?), but the longer term they have the best drug pipeline and growth in the sector. OK for a long term hold.
Show full opinionHide full opinion
Eli Lilly & Co. (LLY-N)
March 15, 2005
A little bit of risk in a 3/6 month view as to whether they can retain their patent on Sprizecta (?), but the longer term they have the best drug pipeline and growth in the sector. OK for a long term hold.
TOP PICK
TOP PICK
August 13, 2004
Lots of new products. Rapid profit growth.
Show full opinionHide full opinion
Eli Lilly & Co. (LLY-N)
August 13, 2004
Lots of new products. Rapid profit growth.
TOP PICK
TOP PICK
Powerful balance sheet.
Eli Lilly & Co. (LLY-N)
April 16, 2004
DON'T BUY
DON'T BUY
April 2, 2002
Has a very good pipeline. Getting more competition from generic drugs. Too focused on Prozac.
Show full opinionHide full opinion
Has a very good pipeline. Getting more competition from generic drugs. Too focused on Prozac.
BUY
BUY
December 10, 2001
Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot
Show full opinionHide full opinion
Eli Lilly & Co. (LLY-N)
December 10, 2001
Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot
DON'T BUY
DON'T BUY
October 30, 2001
Some of their drugs are coming off patent and others not doing as well. Prefers Pfizer or J & J.
Show full opinionHide full opinion
Eli Lilly & Co. (LLY-N)
October 30, 2001
Some of their drugs are coming off patent and others not doing as well. Prefers Pfizer or J & J.
HOLD
HOLD
September 10, 2001
Good pipeline for new drugs but prefers Pfizer.
Show full opinionHide full opinion
Eli Lilly & Co. (LLY-N)
September 10, 2001
Good pipeline for new drugs but prefers Pfizer.
DON'T BUY
DON'T BUY
June 5, 2001
Prozac about to go generic.
Show full opinionHide full opinion
Prozac about to go generic.
Showing 31 to 41 of 41 entries